Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Non-cash Items (2021 - 2025)

Historic Non-cash Items for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $5.1 million.

  • Amylyx Pharmaceuticals' Non-cash Items rose 9612.48% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year increase of 9612.48%. This contributed to the annual value of $3.6 million for FY2024, which is 757.25% down from last year.
  • According to the latest figures from Q3 2025, Amylyx Pharmaceuticals' Non-cash Items is $5.1 million, which was up 9612.48% from $4.9 million recorded in Q2 2025.
  • Over the past 5 years, Amylyx Pharmaceuticals' Non-cash Items peaked at $201.8 million during Q4 2022, and registered a low of $1.8 million during Q1 2022.
  • Over the past 5 years, Amylyx Pharmaceuticals' median Non-cash Items value was $5.0 million (recorded in 2025), while the average stood at $33.1 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first skyrocketed by 119113.07% in 2022, then plummeted by 9513.99% in 2023.
  • Quarter analysis of 5 years shows Amylyx Pharmaceuticals' Non-cash Items stood at $15.6 million in 2021, then surged by 1191.13% to $201.8 million in 2022, then tumbled by 86.3% to $27.6 million in 2023, then tumbled by 87.03% to $3.6 million in 2024, then surged by 40.96% to $5.1 million in 2025.
  • Its Non-cash Items stands at $5.1 million for Q3 2025, versus $4.9 million for Q2 2025 and $4.1 million for Q1 2025.